American Journal of Managed Care: Semaglutide Enhances Heart Failure Outcomes in Obesity

Subanalyses presented in one of the first late-breaking science presentations at the 2024 European Society of Cardiology Congress show that semaglutide has potential to improve outcomes among patients with obesity-related heart failure with preserved ejection fraction (HFpEF).

Data from the STEP-HFpEF program show benefits in patients with atrial fibrillation (aFib), as well as improvements in inflammation.

Presented by principal investigator Mikhail Kosiborod, MD, of Saint Luke's Mid America Heart Institute, Kansas City, a subanalysis of data from the STEP-HFpEF and STEP-HFpEF DM trials showed that patients with aFib have greatly benefited from the GLP-1 receptor agonist, with demonstrated improvements in their heart failure–related symptoms, physical limitations, and exercise abilities, as well as biomarkers of inflammation and heart failure.

Read the full American Journal of Managed Care article: Semaglutide Enhances Heart Failure Outcomes in Obesity

Related Content

Apr. 8, 2024

MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Obesity-Related Heart Failure and Type 2 Diabetes
A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and type 2 diabetes had significant improvement in symptoms and physical limitations when taking semaglutide.
Aug. 25, 2023

MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Heart Failure
STEP-HFpEF trial findings were presented during the opening late breaking clinical trial session at the European Society of Cardiology Congress in Amsterdam, Netherlands.